Meta-analysisindependent cross-checkabstract checked★ key study I-SYS-108 in-depth review

Lowering blood pressure saves lives

Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.

Overview

Ettehad D et al.. Lancet 2016 · PMID 26724178 · DOI 10.1016/S0140-6736(15)01225-8

Each 10 mm Hg lower systolic pressure cut major heart and stroke events by 20% and deaths by 13%.

Does the study support the specific claim? No · Methodological quality: high

Original publication

Plain-language summary

Study explained simply
What did the researchers want to find out?

Effects of lowering BP.

How was the study done?

Meta-analysis of 123 RCTs.

How many people, animals or samples were studied?

613,815 people.

What was actually found?

Fewer events and deaths.

How large was the observed effect?

RR 0.80 CVD; 0.87 death.

What do the results mean in everyday life?

Medicines for high blood pressure prevent strokes and deaths.

What are the study's limitations?

Relative effects.

What does it say about Elawady's specific claim?

Contradicts 'zero medicine'.

Do the results apply to Germany and Europe?

High.

What can explicitly not be concluded from this study?

Every drug class equally.

Scientific in-depth review

1. Full reference

Authors
Ettehad D et al.
Journal
Lancet
Year
2016
Identifier
PMID 26724178 DOI 10.1016/S0140-6736(15)01225-8
Verification
verified – PubMed efetch 2026-10-26 + Crossref
Retracted
no
Corrections
none
Extent checked
abstract only
Conflicts of interest and funding

NIHR and Oxford Martin School funding

2. Research question

Effects of blood pressure lowering on cardiovascular events and death

3. Study design and population

Study design
Meta-analysis – Systematic review and meta-analysis of large blood-pressure-lowering RCTs
Population

Participants of 123 RCTs

Country

International

Period

1966-2015

Sample size

123 studies, 613,815 participants

Inclusion and exclusion criteria

RCTs with >=1000 patient-years per arm

4. Methods and endpoints

Exposure / intervention

Blood-pressure-lowering treatment

Comparator

Control/less intensive

Endpoints

Major CVD, CHD, stroke, heart failure, renal failure, all-cause mortality

Statistical methods

Fixed-effect meta-analysis; meta-regression

5. Actual results

Results

Per 10 mm Hg systolic reduction: major CVD events RR 0.80 (0.77-0.83), CHD 0.83, stroke 0.73 (0.68-0.77), heart failure 0.72, all-cause mortality 0.87 (0.84-0.91); renal failure 0.95 (0.84-1.07). Risk of bias low in 113 trials.

Absolute risks

not reported in abstract

Authors' conclusion

Blood pressure lowering significantly reduces vascular risk across baseline levels and comorbidities.

6. Strengths

  • Very large RCT evidence
  • Low risk of bias

7. Weaknesses

  • Absolute effects depend on baseline risk

8. Risk of bias

Orienting tool
AMSTAR 2
Type of assessment
simplified assessment (abstract only)
Full formal assessment
no
Overall risk of bias
low
Rationale

Systematic, RCT-based.

9. Assessment of the statistical interpretation

CI asymmetries due to 2-decimal rounding of narrow intervals.

10. Relevance to the specific claim

Shows that a laboratory/clinical marker (blood pressure) is causal: lowering it with medicines prevents events and death; refutes 'zero medicine' and 'markers are only signals'.

11. Independent contrary findings

12. Transferability to Germany and Europe

High.

13. Overall methodological judgement

High-certainty evidence against blanket rejection of medicines and of risk markers.

Multidimensional assessment
Multidimensional assessment
Authenticity of the sourceverified
Methodological qualityhigh
Risk of biaslow
Precision of resultshigh
Directnessdirect
Reproducibilityreplicated
Consistency with the overall evidenceconsistent
Regional transferabilityhigh
Adequacy of the interpretation (by the archive)not applicable

14. Open questions

15. Linked fact checks